Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment

Pasireotide improves hypercortisolemia and induces hyperglycemia via somatostatin receptor type‐5 stimulation. GLP‐1RA and SGLT2 inhibitor potentially help regulate hyperglycemia in patients with Cushing's disease, especially after pasireotide administration.

Detalles Bibliográficos
Autores principales: Shikata, Masato, Ashida, Kenji, Goto, Yuka, Nagayama, Ayako, Iwata, Shimpei, Yano, Mamiko, Hasuzawa, Nao, Hara, Kento, Mawatari, Kazutoshi, Sakata, Kiyohiko, Tsuruta, Munehisa, Wada, Nobuhiko, Nomura, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752440/
https://www.ncbi.nlm.nih.gov/pubmed/33363790
http://dx.doi.org/10.1002/ccr3.3230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752440/
https://www.ncbi.nlm.nih.gov/pubmed/33363790
http://dx.doi.org/10.1002/ccr3.3230

Ejemplares similares